ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company that develops, manufactures, and markets branded and generic prescription pharmaceutical products. The company operates across several therapeutic areas, including rare disease, ophthalmology, nephrology, and acute care, with a focus on diseases with high unmet medical need. Its lead asset, Purified Cortrophin® Gel, serves the rare disease business, while its generics segment is supported by enhanced research and development capability.
The company's technical operations span hormone manufacturing, solid dose and liquid dose manufacturing, controlled substances manufacturing, contract manufacturing, packaging, and research and development. ANI Pharmaceuticals maintains a workforce of 501–1,000 employees across its U.S. operations, with facilities in Baudette, Minnesota; Princeton, New Jersey; and East Windsor, New Jersey.
For professionals working at the intersection of pharmaceutical manufacturing, data, and AI, ANI Pharmaceuticals presents opportunities across its R&D and manufacturing functions. The company's scope - covering branded and generic products, rare disease therapeutics, and contract manufacturing - creates a range of technical challenges in drug development, production optimisation, and supply chain management.
